Transport Characteristics of Candesartan in Human Intestinal Caco-2 Cell Line

被引:22
作者
Zhou, Lingjie [1 ]
Chen, Xiaoping [1 ]
Gu, Yuanqing [1 ]
Liang, Jianying [1 ]
机构
[1] Fudan Univ, Sch Pharm, Dept Pharmaceut Anal, Shanghai 200032, Peoples R China
关键词
candesartan; Caco-2; cells; P-glycoprotein; intestinal absorption; P-GLYCOPROTEIN; CLINICAL PHARMACOKINETICS;
D O I
10.1002/bdd.664
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The intestinal absorptive characteristics and the efflux mechanisms of candesartan (CDS), a novel angiotensin II type 1 receptor blocker, were investigated. The Caco-2 cells were used as models of the intestinal mucosa to assess uptake and transport of CDS. The determination of CDS was performed by HPLC-Flu. In the Caco-2 cells, the uptake and absorptive transport of CDS were pH-independent (in the pH range 6.0-8.0). Passive membrane diffusion dominates the absorptive transport behavior of CDS across Caco-2 cells, while secretory transport was a concentration-dependent and saturable process. In the presence of cyclosporin A and verapamil, potent inhibitors of P-glycoprotein (P-gp), the P-ratio decreased from 3.8 to 2.3 and 1.8, respectively, and permeation of apical to basolateral was enhanced. Overall, the current study suggests that efflux transporters are capable of mediating the absorption and secretion of CDS, and they may play significant roles in limiting the oral absorption of CDS. Copyright (C) 2009 John Wiley & Sons, Ltd.
引用
收藏
页码:259 / 264
页数:6
相关论文
共 17 条
[1]   Caco-2 monolayers in experimental and theoretical predictions of drug transport (Reprinted from Advanced Drug Delivery Reviews, vol 22, pg 67-84, 1996) [J].
Artursson, P ;
Palm, K ;
Luthman, K .
ADVANCED DRUG DELIVERY REVIEWS, 2001, 46 (1-3) :27-43
[2]  
Bakris G, 2001, J Clin Hypertens (Greenwich), V3, P16, DOI 10.1111/j.1524-6175.2001.00826.x
[3]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[4]   Cell cultures as tools in biopharmacy [J].
Braun, A ;
Hämmerle, S ;
Suda, K ;
Rothen-Rutishauser, B ;
Günthert, M ;
Krämer, SD ;
Wunderli-Allenspach, H .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2000, 11 :S51-S60
[5]   Angiotensin II type 1 receptor blockers [J].
Burnier, M .
CIRCULATION, 2001, 103 (06) :904-912
[6]  
Contreras Freddy, 2003, Am J Ther, V10, P401, DOI 10.1097/00045391-200311000-00005
[7]   Clinical aspects of the MDRI (ABCB1) gene polymorphism [J].
Eichelbaum, M ;
Fromm, MF ;
Schwab, M .
THERAPEUTIC DRUG MONITORING, 2004, 26 (02) :180-185
[8]   Clinical pharmacokinetics of candesartan [J].
Gleiter, CH ;
Mörike, KE .
CLINICAL PHARMACOKINETICS, 2002, 41 (01) :7-17
[9]   Evaluation of drug interactions with P-glycoprotein in drug discovery:: In vitro assessment of the potential for drug-drug interactions with P-glycoprotein [J].
Hochman, JH ;
Yamazaki, M ;
Ohe, T ;
Lin, JH .
CURRENT DRUG METABOLISM, 2002, 3 (03) :257-273
[10]  
Hubner R, 1997, J HUM HYPERTENS, V11, pS19